Eli Lilly and Company ($LLY) Stock Forecast: Up 5.2% Today

What is Eli Lilly and Company?

Eli Lilly and Company (LLY) is a pharmaceutical company recognized for its innovative drugs across various therapeutic areas. The market sentiment for LLY has been positive today, experiencing a strong bullish movement.

Why is Eli Lilly and Company going up?

LLY stock is up 5.2% on May 16, 2025 14:41

• A recent 17% decline in LLY stock since Q1 results might have created a buying opportunity for investors seeking to benefit from the decrease.
• Despite concerns regarding its expensive valuation and declining estimates, the company's robust growth prospects are prompting investors to retain LLY stock.
• The bullish movement may be linked to investors reassessing Eli Lilly and Company's long-term potential, resulting in increased buying interest and driving up the stock price.

LLY Price Chart

LLY Technical Analysis

LLY News

Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects.

https://www.zacks.com/stock/news/2470211/lilly-down-17-since-q1-results-should-you-buy-the-dip-in-lly-stock

Trending Today

Eli Lilly and Company Price History

17.03.2025 - LLY Stock was up 15.4%

• Eli Lilly's stock soared after its oral GLP-1 drug, Orforglipron, successfully met Phase 3 goals in a diabetes trial, showing promising results in reducing A1C levels and weight in patients.
• Analysts are optimistic about the global potential of Orforglipron, with sales forecasts exceeding consensus estimates, leading to increased investor confidence in Eli Lilly's future prospects.
• The launch of Eli Lilly's weight-loss drug, Mounjaro, in India has triggered a craze in the market, showcasing the company's ability to innovate and capture consumer interest in new products.
• The positive news surrounding Eli Lilly's drug developments contrasts with Pfizer's decision to halt obesity pill development due to safety concerns, further highlighting the importance of successful clinical trials in the pharmaceutical industry.

17.03.2025 - LLY Stock was up 11.4%

• Eli Lilly's stock saw a significant rise following positive results from its oral GLP-1 drug, Orforglipron, in a Phase 3 diabetes trial, demonstrating effectiveness in reducing A1C levels and weight for those with type 2 diabetes.
• The introduction of Eli Lilly's weight-loss medication, Mounjaro, into the Indian market sparked enthusiasm among investors, generating increased interest and positive outlook for the company.
• Speculations suggest that Pfizer's decision to halt an obesity drug development program on safety grounds may have contributed to further enhancing investor trust in Eli Lilly's innovative and secure drug portfolio, propelling its stock price upwards.
• In conclusion, Eli Lilly's recent accomplishments in drug trials and strategic product releases have solidified its position as a key player in the pharmaceutical sector. This has attracted investors and fueled the positive momentum in its stock performance.

01.04.2025 - LLY Stock was down 10.2%

• In spite of the strong upward momentum witnessed over the previous month and year, Eli Lilly (LLY) encountered a downward movement in its stock price today.
• This shift can be linked to the company falling short of Q1 earnings expectations, with a -5.11% surprise in earnings and a 0.86% miss in revenue.
• Moreover, the reduction in projected 2025 profit due to IPR&D-related expenses may have influenced investor sentiment, contributing to today's decline in the stock price.
• Investors are advised to keep a close watch on upcoming earnings releases and updates regarding the company's profitability forecast to assess the potential recovery of the stock from the current bearish trend.

01.04.2025 - LLY Stock was down 6.1%

• Despite a positive earnings forecast for the first quarter, Eli Lilly (LLY) saw a significant bearish movement.
• Some market influencers in LLY options trading displayed a bearish sentiment, potentially impacting the stock's downward trajectory.
• Ongoing legal proceedings involving Eli Lilly and Johnson & Johnson regarding alleged health risks associated with their products may have raised investor apprehensions, contributing to the bearish market sentiment.
• Concerns regarding the lawsuit's potential repercussions on Eli Lilly's financial performance and image could be prompting investors to offload the stock.

01.04.2025 - LLY Stock was down 10.7%

• A mix of results was reported by Eli Lilly for Q1, with earnings falling short of estimates while sales surpassed expectations, fueled by strong showings from Mounjaro and Zepbound.
• Despite a 45% increase in Q1 revenue and notable sales performance for key products, the stock saw a decrease, potentially linked to the revised 2025 profit projection tied to substantial IPR&D expenses.
• The market response to Eli Lilly's Q1 results may be connected to the disparity in earnings and revenue surprises, prompting scrutiny from investors about the company's future growth potential.
• Technical analysis pointed towards a bullish trajectory for Eli Lilly's stock; however, investor focus on the profit outlook and potential impact of IPR&D charges from the earnings report led to a bearish market response.

04.03.2025 - LLY Stock was down 6.8%

• Eli Lilly stock saw a notable decline despite a recent license agreement with Sangamo Therapeutics expected to bring in substantial revenue.
• Uncertainty over proposed tariffs on pharmaceutical imports by the current administration has had a negative impact on Eli Lilly, Pfizer (PFE), and Merck (MRK) stocks.
• Although there was smart money interest and support from financial giants, Eli Lilly's stock faced a significant decline, likely influenced by broader market conditions and tariff-related concerns outweighing positive developments.

09.03.2025 - LLY Stock was down 6.9%

• The partnership between Sangamo Therapeutics and Eli Lilly might have caused investors to shift their focus towards Sangamo, leading to a sell-off in LLY.
• Investors may see Sangamo's potential for significant earnings through the license agreement as a more attractive opportunity compared to LLY's current market position.
• The competition between LLY and NVO in the weight-loss drug sector could also be influencing investor sentiment, with some choosing to reallocate their investments from LLY to NVO.

16.04.2025 - LLY Stock was up 5.2%

• A recent 17% decline in LLY stock since Q1 results might have created a buying opportunity for investors seeking to benefit from the decrease.
• Despite concerns regarding its expensive valuation and declining estimates, the company's robust growth prospects are prompting investors to retain LLY stock.
• The bullish movement may be linked to investors reassessing Eli Lilly and Company's long-term potential, resulting in increased buying interest and driving up the stock price.

07.02.2025 - LLY Stock was down 5.2%

• The partnership between Teladoc Health and Eli Lilly's LillyDirect to expand access to Zepbound for weight loss possibly sparked concerns among investors about the competitive landscape in the weight management sector, influencing a bearish sentiment towards Eli Lilly.
• The bullish options activity on Eli Lilly might reflect conflicting sentiments among investors, with some anticipating positive outcomes while others exercise caution, contributing to the stock's downward trend.
• Novo Nordisk's efforts to enhance Wegovy access through reduced pricing and home delivery could have exerted pressure on Eli Lilly's stock as investors reassess the competitive pricing and accessibility of weight management treatments in the market.
• Despite Eli Lilly's historical superior performance over the last two decades, recent developments and competitive pressures in the weight management sector may have cast a shadow on its long-term success, triggering a bearish market movement today.

10.03.2025 - LLY Stock was down 5.4%

• Wealthy investors have taken a pessimistic position on Eli Lilly, as evidenced by the latest options trends, potentially impacting the stock's downturn.
• The announcement of a 90-day pause on tariffs by President Trump benefited pharmaceutical stocks, including Eli Lilly, but the initial effects of the anticipated import tariff had already negatively influenced the stock price.
• The collaboration update with Sangamo Therapeutics could have initially boosted investor confidence. However, various market conditions seemed to overshadow this positive development, contributing to Eli Lilly's stock decline.
• In summary, the combination of bearish options trends, tariff uncertainties, and general market instability likely played a role in the downward trend of Eli Lilly's stock today.

06.01.2025 - LLY Stock was up 3.1%

• Q4 earnings report for Eli Lilly exceeded expectations, showing a 45% YoY revenue increase driven by strong demand for Mounjaro and Zepbound.
• The company's 2025 sales forecast of $58B-$61B, with a 32% growth midpoint, fueled investor optimism and contributed to the bullish momentum in the stock.
• Analysts are bullish on LLY, with price targets averaging $1066, indicating a 27% upside potential, supported by the anticipated success of new medicines and expanded market launches.
• The positive sentiment surrounding Eli Lilly's earnings and future prospects likely led to the strong bullish movement in the stock today.

06.04.2025 - LLY Stock was down 5.2%

• Cutting Eli Lilly's price target to $883 due to PBM-related uncertainty after CVS dropped Zepbound may have caused a lack of investor confidence, contributing to the bearish movement.
• Despite bullish options activity on Eli Lilly, concerns over the setback with CVS and missed earnings in Q1 might have overshadowed the positive sentiment.
• Mixed reactions from analysts and the market's response to the earnings miss despite strong revenue growth suggest investors are cautious about the company's future performance.
• The reduction in 2025 profit outlook, not due to tariffs but IPR&D charges, could have added to the negative sentiment surrounding Eli Lilly, leading to the bearish market movement.